“Have you ever been in an environment full of intellectual people? Now combine that with CRISPR/Cas9. Greatness at full potential.”
Denisse
Sr. Associate Scientist, Mass Spectrometry
Programs
Each one of us together for patients.
Using a modular approach, we optimize the necessary therapeutic components so they can be used and combined in our in vivo and ex vivo programs to develop product candidates addressing a broad range of diseases. As exemplified by our current programs, this approach will allow us and our partners to build a full-spectrum genome editing company, with a pipeline of products that can treat a broad range of genetic and oncological diseases.
Overview
As a pioneer in the development of CRISPR/Cas9-based therapies, we are rapidly moving our development candidates towards the clinic so we can make them available to patients suffering severe and life-threatening disorders.
Our company’s unique strengths include our CRISPR/Cas9 system improvements, modular lipid nanoparticle delivery system and our determined focus on product development.